Impact Biomedical Stock Symbol Overview and Insights

Impact Biomedical's stock symbol is IBIH. This symbol is used to represent the company's shares on various stock exchanges.

The company is a biotechnology firm focused on developing innovative medical solutions. Its research and development efforts aim to create products that improve patient outcomes and quality of life.

IBIH's stock is listed on the OTCQB market, which is a platform for emerging growth companies. This listing allows the company to access a wider investor base and increase its visibility in the market.

For your interest: Subaru Stock Quote

The IPO process is a complex and multi-step process, but let's break it down simply. Impact BioMedical Inc. announced the pricing of its initial public offering, offering 1,500,000 shares of common stock at $3.00 per share.

The company's stock is set to trade on the NYSE American Market, under the ticker symbol 'IBO', and trading is expected to begin on September 16, 2024. Impact BioMedical Inc. has also granted underwriters a 45-day option to purchase an additional 225,000 shares.

The company has agreed to issue underwriter warrants to purchase up to 75,000 shares, exercisable at 125% of the IPO price. This means the underwriters can buy more shares at a higher price if they choose to exercise their option.

Here's an interesting read: Ticker Symbol and Stock Exchange for Given Company Neximmune Inc

The 3F US patent issue is a significant milestone for Impact BioMedical Inc. (NYSE: IBO). The company has announced the issuance of U.S. Patent No. 11,985,973 for its 3F technology platform.

This patent covers natural insect repellent compositions derived from plant constituents and fragrances. These compositions are designed to inhibit insect olfactory receptors, effectively 'blinding' insects to human presence.

The 3F technology has potential applications in mosquito repellents and additives for detergents, shampoos, or lotions. This innovation addresses the global issue of vector-borne diseases.

The patent will expire in February 2039, and the company is now accelerating discussions with potential partners to bring 3F to market in the US and globally. IBO CEO Frank D. Heuszel stated that this patent issuance demonstrates the company's successful business model in delivering unique proprietary technology for unmet healthcare needs.

Consider reading: Us Cellular Ticker Symbol